EGFR and head and neck squamous cell carcinoma: The importance of this investigation lies in the fact that the only FDA approved targeted therapy for locoregionally advanced HNSCC is the anti-EGFR antibody Cetuximab, for which exists conflicting results about its efficacy [28].